C-0MX7Attralus
pan-amyloid removal, biologics, amyloid imaging
clearingbiologic
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-0MX7
C-0MX7C-0MX7pan-amyloid removal, biologics, amyloid imaging
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Attralus states that systemic amyloidosis is a severely debilitating, progressive, and often fatal set of diseases with major unmet needs in both diagnosis and treatment. The company’s stated belief is that novel pan-amyloid targeting agents can improve outcomes by enabling earlier and more comprehensive detection of amyloid throughout the body and by directly targeting and removing toxic amyloid deposits from organs and tissues, supporting a more holistic approach to detecting, monitoring, targeting, and clearing systemic amyloid.
SourceAttralus states that systemic amyloidosis is a severely debilitating, progressive, and often fatal group of diseases with major unmet diagnostic and therapeutic needs. The company believes earlier detection and better treatment are possible across many amyloid subtypes, and that pan-amyloid targeting agents can both illuminate amyloid deposition throughout the body and directly bind and help remove toxic amyloid fibrils from organs and tissues. It presents this as a holistic strategy to detect, monitor, target, and clear systemic amyloid in order to improve survival and quality of life.
SourceAttralus states that systemic amyloidosis is a serious, often fatal set of diseases with major unmet need, including widespread underdiagnosis and a lack of therapies that remove amyloid or work across all disease types and stages. The company’s stated belief is that directly binding to and removing toxic amyloid with pan-amyloid removal therapeutics can modify disease, potentially reverse it, and transform treatment beyond therapies that only slow progression.
Source